Livagen (KED)

Substance: Lys-Glu-Asp (synthetic tripeptide) · Target tissue: Liver / gene expression

Liver-derived synthetic tripeptide marketed for gene-expression effects; minimal published record outside the institute.

Extract counterpart: None established — this compound exists only as a defined synthetic fragment.

Matched publications in database: 1 (EXTRACT 0, SYNTHETIC 0, EXTRACT→SYN 0)

Extract vs synthetic gap: the human outcome data (including the 266-patient mortality cohort) was collected on extracts; vendors sell synthetic fragments. No head-to-head trial exists — evidence does not transfer between them. Details →

Khavinson studies (1 matched, 2002)

Keyword-filtered from the 472-publication database (khavinson.info). EXTRACT/SYNTHETIC tags are title-text heuristics — verification is on the reader. Full tag legend: evidence-tiers.html

[169] Khavinson V.Kh., Lezhava T.A., Monaselidze J.G., Dzhokhadze T.A., Dvalishvili N.A., Bablishvili N.K., Ryadnova I.Yu. Effects of Livagen Peptide on Chromatin Activation in Lymphocytes from Old People. // Bulletin of Experimental Biology and Medicine. - 2002. - Vol. 134, N 4. - P. 389-392. (2002)untag

Independent (non-Khavinson) studies

None catalogued. To date there are zero independent Western human trials of any Khavinson compound, in any year. Independent in-vitro data exists for Epitalon only (two 2025 studies). If a study belongs here, add it to non-khavinson-research.json and rebuild.

Reddit meta-scrape

No Reddit community discussion exists for this compound. This is honest reporting — the peptide has essentially zero anecdotal footprint in the biohacking community. Absence of anecdotes is not evidence of safety or efficacy, but it does mean there is no community-level signal to analyze.

Measurement protocol — concrete testable endpoints

Liver panel (ALT/AST/GGT), lymphocyte subset analysis.

All endpoints on one page: measurement-protocols.html · Evidence-tier legend: evidence-tiers.html

← Cartalax (AED) Directory Vesugen (KED) →